Fig. 2. Prevention and reversal of diabetic cardiomyopathy in the Elmo1H/H Ins2Akita/+ (HHAkita) mice treated with B12 at 10 mg/kg bw/day.
a Representative M-mode echocardiograms. Black bar, 0.1 s; Red bar, 0.1 mm. b Representative tissue Doppler imaging. Black bar, 0.1 s; Red bar, 50 mm/s. c LVEF, d LVPWd, e LVIDd, f EWDR, g IVRT and h E’ in mice at age 8, 16, and 24 weeks. HHAkita mice were given 10 mg/kg bw/day of B12 in the drinking water starting at 8 weeks of age (preventive protocol, B12P; blue lines; N = 9) or starting at 16 weeks of age (therapeutic protocol, B12T; black lines; N = 10). Data are expressed as means ± standard errors. The numbers of untreated mice (red lines) were 10 at age 8 and 16 weeks and 7 at age 24 weeks). *P < 0.05 vs. mice with non-supplemented drinking water by Tukey–Kramer Honestly Significant Differences test. Dotted lines in the figures indicate average levels in non-diabetic Elmo1H/H Ins2+/+ mice.